The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials
Summary: In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients. Often patients in remote and rural regions and those in low...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | The Lancet Regional Health. Western Pacific |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266660652500029X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861206601957376 |
|---|---|
| author | Rebekah M. Ahmed Olivier Piguet Catherine J. Mummery Sharon L. Naismith Muireann Irish |
| author_facet | Rebekah M. Ahmed Olivier Piguet Catherine J. Mummery Sharon L. Naismith Muireann Irish |
| author_sort | Rebekah M. Ahmed |
| collection | DOAJ |
| description | Summary: In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients. Often patients in remote and rural regions and those in low income regions are disadvantaged. Many clinical trials for dementia patients are biased to recruiting a homogenous group of patients that does not represent cultural and linguistic diversity, meaning the generalisability of trials is limited. This viewpoint discusses the barriers to access to early treatments and clinical trials for patients with dementia and offers a potential framework to address these including provision of infrastructure, regulatory change and patient education. |
| format | Article |
| id | doaj-art-b37f7f7ead8b4fd991cce1a4cce0ad43 |
| institution | Kabale University |
| issn | 2666-6065 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Western Pacific |
| spelling | doaj-art-b37f7f7ead8b4fd991cce1a4cce0ad432025-02-10T04:34:59ZengElsevierThe Lancet Regional Health. Western Pacific2666-60652025-02-0155101492The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trialsRebekah M. Ahmed0Olivier Piguet1Catherine J. Mummery2Sharon L. Naismith3Muireann Irish4Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia; Brain and Mind Centre, University of Sydney, Australia; Corresponding author. Department of Neurology, Royal Prince Alfred Hospital, Missenden Rd, Sydney, NSW, 2050, Australia.Brain and Mind Centre, University of Sydney, Australia; School of Psychology, The University of Sydney, AustraliaDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UKBrain and Mind Centre, University of Sydney, Australia; School of Psychology, The University of Sydney, AustraliaBrain and Mind Centre, University of Sydney, Australia; School of Psychology, The University of Sydney, AustraliaSummary: In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients. Often patients in remote and rural regions and those in low income regions are disadvantaged. Many clinical trials for dementia patients are biased to recruiting a homogenous group of patients that does not represent cultural and linguistic diversity, meaning the generalisability of trials is limited. This viewpoint discusses the barriers to access to early treatments and clinical trials for patients with dementia and offers a potential framework to address these including provision of infrastructure, regulatory change and patient education.http://www.sciencedirect.com/science/article/pii/S266660652500029XDementiaAlzheimer's diseaseMono-clonal antibodiesTreatmentFrototemporal dementia |
| spellingShingle | Rebekah M. Ahmed Olivier Piguet Catherine J. Mummery Sharon L. Naismith Muireann Irish The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials The Lancet Regional Health. Western Pacific Dementia Alzheimer's disease Mono-clonal antibodies Treatment Frototemporal dementia |
| title | The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials |
| title_full | The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials |
| title_fullStr | The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials |
| title_full_unstemmed | The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials |
| title_short | The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials |
| title_sort | holy grail highlighting the need for equitable access to dementia treatments and clinical trials |
| topic | Dementia Alzheimer's disease Mono-clonal antibodies Treatment Frototemporal dementia |
| url | http://www.sciencedirect.com/science/article/pii/S266660652500029X |
| work_keys_str_mv | AT rebekahmahmed theholygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT olivierpiguet theholygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT catherinejmummery theholygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT sharonlnaismith theholygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT muireannirish theholygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT rebekahmahmed holygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT olivierpiguet holygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT catherinejmummery holygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT sharonlnaismith holygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials AT muireannirish holygrailhighlightingtheneedforequitableaccesstodementiatreatmentsandclinicaltrials |